Dr. Vlad Codrea, MD, PhD

Dr. Codrea practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Codrea's NPI, 1588059646, was assigned on April 4, 2015. Dr. Codrea graduated from University of Texas Medical Branch at Galveston in 2015. Dr. Codrea holds West Virginia license 29743.

Dr. Codrea's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Codrea's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Codrea is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Codrea to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Codrea practices, 4 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Codrea's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dmand AI has Dr. Codrea's licenses on file in 2 states: West Virginia and Texas.

CMS data shows 1,310 Medicare services from Dr. Codrea across 17 procedure codes in 2024, for 324 Medicare patients. Medicare paid $126,295 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 324 Medicare patients who saw Dr. Codrea in 2024. The largest group is 75 to 84, with 131 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Codrea's median patient age at 75, with 36% women.

In 2024, Dr. Codrea wrote 632 Medicare Part D claims for 458 patients. 98% of them were for generic drugs. CMS names the drug for 573 of them, across 6 drugs with 11 or more claims each, at $7,221 in total drug cost. In 2023, CMS named 388 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Codrea for performance year 2024, reported through an alternative payment model (APM). Dr. Codrea accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Codrea as offering telehealth. CMS counts 71 procedures of removal of skin lesions by Dr. Codrea, more than 73% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 13 papers to Dr. Codrea, published from 2011 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Skin Neoplasms, Ear, External and Mohs Surgery. Dr. Codrea has published most often in Dermatol Surg. Dr. Codrea's most frequent co-authors are Richard F. Wagner, MD, Aaron Kriss Joseph, MD and Jason Matthew Hirshburg, MD, PhD.

CMS Open Payments shows 24 general payments to Dr. Codrea from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Abbvie Inc. paid the most, $920.

Dr. Codrea graduated from University of Texas Medical Branch at Galveston in 2015.